Form 4: Johnson & Johnson Executive Kristen Mulholland Reports Stock Option and Restricted Share Unit Awards

EVP, Chief HR Officer of Johnson & Johnson, Kristen Mulholland, reports the acquisition of stock options and restricted share units under the company's Long-Term Incentive Plan.

Summary

• Kristen Mulholland, EVP, Chief HR Officer of Johnson & Johnson, filed a Form 4 on February 19, 2025.
• The filing reports the acquisition of 27,951 employee stock options with an exercise price of $156.15, awarded under the Issuer's Long-Term Incentive Plan on February 15, 2025.
• These stock options vest in three equal annual installments starting on the first anniversary of the grant date and expire on February 15, 2035.
• Mulholland also acquired 1,725 Restricted Share Units (RSUs) on February 15, 2025, also awarded under the Issuer's Long-Term Incentive Plan.
• These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date and convert into shares of Common Stock on a one-for-one basis upon vesting.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the company's future.

Positives

• The grant of stock options and RSUs aligns Mulholland's interests with those of the shareholders, incentivizing her to drive long-term value creation.
• The vesting schedule of the awards encourages continued service and commitment to the company.

Future Outlook

The vesting schedule of the stock options and RSUs suggests a continued commitment by Mulholland to Johnson & Johnson's long-term performance.

Industry Context

Stock option and RSU grants are a common practice in executive compensation packages within the pharmaceutical and healthcare industry, aligning executive incentives with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice among large pharmaceutical companies like Pfizer (PFE), Merck (MRK), and AbbVie (ABBV).
• The vesting schedules and grant sizes are typically benchmarked against peer companies to ensure competitiveness and retention of key personnel.
• The specific terms of Mulholland's awards would likely be comparable to those offered to executives in similar roles at these companies.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants positively, as they align executive compensation with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates